A plethora of drugs are available for the treatment of T2DM; incretin-based therapies such as dipeptidyl peptidase-4(DPP-4) inhibitors and glucagon like peptide-1(GLP-1) receptor agonists are among the recent additions to the therapeutic armamentarium in T2DM [2]. This evidence concerns the gene GCG and type 2 diabetes mellitus.